CRO concept stocks fell again. As of press release, Kanglong Chemical (03759) fell 4.37% to HK$9.4; Tiger Pharmaceuticals (03347) fell 2.33% to HK$25.1; and Zhaoyan Pharmaceutical (06127) fell 2.11% to HK$10.2. Only Medicinal Kangde (02359) reversed the market and rose by 2.94% to HK$42.
The Zhitong Finance App learned that CRO concept stocks fell again. As of press release, Kanglong Chemical (03759) fell 4.37% to HK$9.4; Tiger Pharmaceuticals (03347) fell 2.33% to HK$25.1; and Zhaoyan Pharmaceutical (06127) fell 2.11% to HK$10.2. Only Medicinal Kangde (02359) reversed the market and rose by 2.94% to HK$42.
According to the news, Yao Ming Kangde once again issued a clarification notice in response to the previous “four US lawmakers sent a letter to US government departments requesting sanctions against Pharmaceutical Ming,” reaffirming that “Pharmaceutical Kangde did not pose a national security risk to the US in the past, now, or in the future, and will come to the same conclusion even if the US government reviews the company again.” In addition, Yao Ming Kangde mentioned that the company has no human genomics business, and the various existing businesses do not collect human genomics data.
CITIC Construction Investment pointed out that at present, first-level investment and financing in the pharmaceutical sector still needs to be resumed, and the downstream demand side needs to improve. Furthermore, the industry has recently been greatly affected by the “Biosafety Act” introduced by both houses of the Senate. Currently, both houses are advancing similar laws, but they are in the early stages. Further progress and potential effects still need to be observed. The major companies involved in the bill have also clarified the untruths.